MEDS — DataMeds AI Share Price
Last trade - 00:00- $11.01m
- $40.36m
- $23.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1033.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 18.13 | 23.34 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- September 6th, 2022
- Public Since
- February 21st, 2025
- No. of Shareholders
- 46
- No. of Employees
- 31
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,864,300
- Address
- 3000 Bayport Drive Suite 950, TAMPA, 33607
- Web
- https://datamedsai.com
- Phone
- +1 8433021785
- Auditors
- Suri & Co.
Latest News for MEDS
Upcoming Events for MEDS
Q3 2026 DataMeds AI Inc Earnings Release
Q4 2026 DataMeds AI Inc Earnings Release
Similar to MEDS
20/20 Biolabs
NASDAQ Capital Market
Accuray Incorporated
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
AdaptHealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
FAQ
As of Today at 02:13 UTC, shares in DataMeds AI are trading at $2.85. This share price information is delayed by 15 minutes.
Shares in DataMeds AI last closed at $2.85 and the price had moved by -90.19% over the past 365 days. In terms of relative price strength the DataMeds AI share price has underperformed the S&P500 Index by -91.6% over the past year.
There is no consensus recommendation for this security.
Find out moreDataMeds AI does not currently pay a dividend.
DataMeds AI does not currently pay a dividend.
DataMeds AI does not currently pay a dividend.
To buy shares in DataMeds AI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.85, shares in DataMeds AI had a market capitalisation of $11.01m.
Here are the trading details for DataMeds AI:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MEDS
Based on an overall assessment of its quality, value and momentum DataMeds AI is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DataMeds AI. Over the past six months, its share price has underperformed the S&P500 Index by -63.66%.
As of the last closing price of $2.85, shares in DataMeds AI were trading -58.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The DataMeds AI PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on DataMeds AI's directors